AbstractBackgroundSome case reports have described parkinsonism with amiodarone. We investigated a putative association between parkinsonism and exposure to amiodarone.MethodsWe used the WHO pharmacovigilance database (VigiBase®). All adverse drug reactions with ‘Parkinson‐like events’ and amiodarone were included. Four disproportionality analyses were performed: 1/after inclusion of all reports, 2/according to sex, 3/for the twenty last years (2000–2019), and 4/after exclusion of concomitant drugs known to induce parkinsonism (antipsychotic, antivertigo, antiemetic antinauseant drugs, flunarizine). Results are expressed as reporting odds ratios (ROR; 95% CI) and information component (IC).ResultsNo significant association was found in the whole population [ROR = 0.83 (0.65–1.06), IC = −0.7 (IC025 = −0.65)], in men, in women, for the 2000–2019 years, or after exclusion of drugs inducing parkinsonism.ConclusionWe failed to find any signal of parkinsonism with amiodarone. We suggest that reports of parkinsonism with amiodarone could be mainly explained by other underlying causes.